InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (10 ops.)
Browse the detailed record of transactions filed by Nicolas Dano, Chief Operating Officer et Chief Commercial Officer – iCRO. Insider active across 1 companies, notably Median Technologies. Aggregated, 22 reports have been recorded. Total volume traded: €184k. The latest transaction was filed on 21 October 2025 (Acquisition). Regulator: AMF. The full history is free.
Declarations22 total
€24,0007,500 shares@ €3.200.035% mcap12.0% of flow
ActionEuronext Growth Paris
2025DD1065529·
Ideal exit: 18 Jul 2026 (T+270)
€6,3802,000 shares@ €3.190.0092% mcap3.2% of flow
ActionEuronext Growth Paris
2025DD1059415·
€11,3804,000 shares@ €2.8450.016% mcap5.7% of flow
ActionEuronext Growth Paris
2025DD1057596·
€5,3802,000 shares@ €2.690.0077% mcap2.7% of flow
ActionEuronext Growth Paris
2025DD1053940·
€4,6402,000 shares@ €2.320.0067% mcap2.3% of flow
ActionEuronext Growth Paris
2025DD1053604·
€100,00260,242 shares@ €1.660.14% mcap49.9% of flow
ActionEuronext Growth Paris
2025DD1053614·
Ideal exit: 2 May 2026 (T+270)
€3,9882,000 shares@ €1.9940.0057% mcap2.0% of flow
ActionEuronext Growth Paris
2025DD1053615·
€5,8751,000 shares@ €5.87510.0085% mcap2.9% of flow
ActionEuronext Growth Paris
2024DD994378·
€1,5001,000 shares@ €1.500.0022% mcap0.7% of flow
Option d'achatEuronext Growth Paris
2024DD994379·
€5,3581,000 shares@ €5.35750.0077% mcap2.7% of flow
ActionEuronext Growth Paris
2024DD994380·
€4,9641,000 shares@ €4.96440.0071% mcap2.5% of flow
ActionEuronext Growth Paris
2024DD994372·
€1,5001,000 shares@ €1.500.0022% mcap0.7% of flow
Option d'achatEuronext Growth Paris
2024DD994373·
€6,7071,000 shares@ €6.70720.0096% mcap3.3% of flow
ActionEuronext Growth Paris
2024DD994374·
€1,5001,000 shares@ €1.500.0022% mcap0.7% of flow
Option d'achatEuronext Growth Paris
2024DD994375·
€5,3361,000 shares@ €5.33640.0077% mcap2.7% of flow
ActionEuronext Growth Paris
2024DD994376·
€1,5001,000 shares@ €1.500.0022% mcap0.7% of flow
Option d'achatEuronext Growth Paris
2024DD994377·
€1,5001,000 shares@ €1.500.0022% mcap0.7% of flow
Option d'achatEuronext Growth Paris
2024DD994369·
07,500 shares0
ActionHors plateforme de négociation
2023DD938817·
Ideal exit: 17 Jul 2024 (T+270)
€9,0006,000 shares@ €1.500.013% mcap4.5% of flow
Option d'achatHors plateforme de négociation
2023DD938051·
07,500 shares0
Actions gratuitesHors plateforme de négociation
2022DD873598·
030,000 shares0
ActionHors plateforme de négociation
2021DD795877·
030,000 shares0
ActionEuronext Growth Paris
2021DD736926·
Ideal exit: 8 Dec 2021 (T+270)
22 of 22 declarations
About Nicolas Dano
Nicolas Dano holds a key leadership position at MEDIAN TECHNOLOGIES as Chief Operating Officer and Chief Commercial Officer of the iCRO Business Unit. In this role, he oversees the company’s medical imaging services for clinical trials, spanning research and development, operations, project delivery, and the commercialization of imaging services. His scope sits at the center of MEDIAN’s business model, which combines image analysis expertise, artificial intelligence innovation, and services for healthcare and pharmaceutical clients. With more than 25 years of experience in the healthcare industry, Nicolas Dano has built a career focused on innovation, technology, and high-value services. Before joining MEDIAN TECHNOLOGIES, he worked as a Senior Research Scientist at General Electric, where he developed strong technical expertise in imaging and medical device environments. His background reflects a rare combination of scientific depth and the ability to translate that knowledge into business development and operational execution. At MEDIAN, he has played an important role in strengthening the company’s position in the clinical imaging market, including relationships with major pharmaceutical sponsors. He is known for a customer-oriented approach, continuous process improvement, and a strong emphasis on automation and operational efficiency to support the growth and profitability of the iCRO business. His recent public statements also highlight MEDIAN’s strategic positioning in the United States and its ability to support clinical trial sponsors with best-in-class imaging solutions. Nicolas Dano holds a Master of Science in Computer Vision and an Executive MBA from HEC Paris. This educational background, combined with his international experience, gives him a hybrid executive profile that blends technical credibility, commercial acumen, and managerial leadership—an especially relevant combination for medtech and digital health companies.
